A Big Day for the Johnson & Johnson Single-dose COVID-19 Vaccine
Following the unanimous endorsement from an FDA panel, it will be shocking if the single-dose vaccine doesn't get an EUA.
When the histories of the COVID-19 pandemic are written, today and the ones following are likely to stand out. A single-dose vaccine against the disease got the go-ahead.
The FDA Vaccines and Related Biological Products Advisory Products Advisory Committee unanimously endorsed the third U.S. COVID-19 vaccine, produced by Janssen, a subsidiary of Johnson & Johnson (J&J). An emergency use authorization by the FDA is expected to follow shortly.
An FDA briefing document for the committee said the vaccine was 66.1% effective against moderate-to-severe COVID-19. The briefing document, which is a review of the data submitted by Johnson & Johnson by FDA staffers, says lower effectiveness was seen in a subgroup of the study volunteers in the phase 3 trial who were 60 and older with comorbidities. That difference narrowed, though, once the scope of the analysis was broadened. The briefing document says a safety analysis through Jan. 22 that included a median follow-up period of two months “supported a favorable safety profile with no specific safety concerns identified that would preclude issuance of an EUA.”
The committee of outside experts will consider other evidence besides the briefing document. And the committee has just advisory role to the agency.
It would be shocking if the committee didn’t recommend an EUA for the Johnson & Johnson vaccine and if the FDA didn’t issue one, maybe as soon as tomorrow.
The Johnson & Johnson is considerably less effective than the two-dose Pfizer-BioNTech and Moderna vaccines, which are 95% effective. But the Johnson & Johnson vaccine has the advantage of being a single dose. Moreover, it’s 85% effectiveness against severe COVID-19 cases approaches that of the Pfizer-BioNTech and Moderna vaccines.
Helen Branswell at Stat has cautioned against side-by-side comparisons of the vaccines because there were subtle but perhaps importance difference endpoints of the trials and how and when COVID-19 cases were counted. Also, the Pfizer-BioNTech and Moderna trials were conducted before the U.K. and South African variants emerged.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Ohio’s Medicaid Work Requirement Efforts Aim to Boost Engagement, Avoid Coverage Loss
April 18th 2025Maureen Corcoran, director of the Ohio Department of Medicaid, believes the work requirement policy can be both a financial and moral effort to improve the lives of Medicaid consumers.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Why Better Data and Awareness Matters for Medicaid Work Requirements
April 17th 2025With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
Read More
